Teysuno launched for advanced gastric cancer

Teysuno (tegafur/gimeracil/oteracil) is indicated for use in combination with cisplatin for advanced gastric cancer.

Effective contraception is required during and for 6 months after treatment with Teysuno
Effective contraception is required during and for 6 months after treatment with Teysuno

PHARMACOLOGY

Teysuno is an oral fluoropyrimidine antineoplastic agent. It is a fixed dose combination of three active substances: tegafur, which after absorption is converted into 5-fluorouracil (5-FU); gimeracil, a dihydropyrimidine dehydrogenase (DPD) inhibitor that prevents degradation of 5-FU by the body; and oteracil, an orotate phosphoribosyltransferase (OPRT) inhibitor that decreases the activity of 5-FU in normal gastrointestinal mucosa. This combination maintains 5-FU exposure to sustain anti-tumour activity while reducing toxicity associated with 5-FU alone.1

CLINICAL STUDIES

The FLAGS Trial conducted in 24 countries randomised 1,053 patients to receive intravenous cisplatin plus either 5-FU by intravenous infusion or the fixed-dose combination of tegafur, gimeracil and oteracil (molar ratio 1.0:0.4:1.0) by mouth. Patients received 5-FU at 1g/m2/24 hours for 120 hours and cisplatin 100mg/m2 on day 1, repeated every 28 days (n=526) or the fixed-dose combination at 50mg/m2 daily (expressed as tegafur dose) in 2 divided doses for 21 days and cisplatin at 75mg/m2 on day 1, repeated every 28 days (n=527).2

The primary endpoint was superiority in overall survival from cisplatin plus combination therapy and cisplatin plus 5-FU in patients with advanced, untreated gastric or gastroesophageal adenocarcinoma. The secondary endpoints were response rate, progression-free survival, time to treatment failure and safety.2

Median overall survival was 8.6 months in the cisplatin/fixed-dose combination group and 7.9 months in the cisplatin/5-FU group (HR 0.92; 95% CI 0.80 to 1.05; p=0.20).2

Whilst the cisplatin/fixed-dose combination did not prolong the overall survival of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/5-FU, it did have a significantly improved safety profile.

The incidence of grade 3/4 neutropenia was reduced in the cisplatin/fixed-dose combination group compared with the cisplatin/5-FU group (32.3% versus 63.6%; p<0.01), as was the incidence of complicated neutropenia (5.0% versus 14.4%; p≤0.01).2

References:

  1. Teysuno Summary of Product Characteristics, March 2011.
  2. Ajani JA et al. J Clin Oncol 2010; 28: 1547-53.

View Teysuno drug record

Further information: Nordic Pharma Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases